Puerto Rico

The most important policy fact is the absence of a dedicated Puerto Rico psychedelic reform architecture. Instead, the relevant machinery sits inside the existing controlled-substances framework, under the Secretary of Health. The law’s automatic-response provision for federal scheduling changes means Puerto Rico could move quickly if federal status changes, but it has not done so independently for psilocybin or MDMA in the materials reviewed.###

Puerto Rico also has a formal mental-health and addiction-services apparatus through the Mental Health and Addiction Services Administration framework, but nothing in the sources reviewed showed that it had launched a psychedelic-specific task force, therapeutic pilot or reimbursement pathway. For a professional audience, the key point is that the territory currently looks like a conventional controlled-substances jurisdiction with pockets of ketamine provision rather than a policy-led psychedelic market.###

Puerto Rico’s law expressly authorises the Secretary of Health to support education and research programmes involving controlled substances, which means there is at least a statutory basis for lawful research activity under local oversight. That said, the public-facing research signal is thin compared with larger mainland states.###

In the sources reviewed, the strongest verified local signal was clinical service activity rather than a major classical-psychedelic trial platform. No territory-based classical psychedelic trial site was confirmed from the materials gathered here, so This should be treated Puerto Rico as a low-visibility research environment pending stronger registry or institutional confirmation.###

Operational authority is concentrated in the Department of Health. The Controlled Substances Act covers registration, inspection, administrative hearings, advisory committees and training of inspectors, which means Puerto Rico has legal machinery for controlled-substance governance already in place. That is relevant if federal scheduling changes eventually require local implementation, but there is no verified psychedelic-specific rulemaking track under way now.###

For access implementation, the practical bottleneck is not a bespoke local licensing system for psychedelic services; it is the lack of any such system. Provider availability therefore depends on ordinary licensed medical practice for ketamine and REMS-certified esketamine settings rather than on state-style service centres or facilitator licensing.###

The verified on-island ecosystem appears small and service-led. Mente Sana PR publicly markets ketamine infusion services, and the Pravan Foundation says it is working with Pravan Clinic to introduce ketamine-assisted psychotherapy locally. These are meaningful ecosystem markers, but they are still private/provider initiatives rather than evidence of a broad regulated market.###

Puerto Rico also has substantial conventional mental-health infrastructure, including Hospital Panamericano’s island-wide outpatient network, which may matter for future partnerships and referral patterns even though it is not, on present evidence, a classical psychedelic hub.###

Over the next 12 to 24 months, Puerto Rico is more likely to see incremental growth in ketamine and esketamine service provision than a stand-alone territorial psychedelic regime. That is because the legal and administrative base already supports controlled-substance oversight, while no verified legislative or agency push for broader psychedelic reform appeared in the reviewed material.###

The main upside scenario is external rather than internal: a federal approval, rescheduling or expanded lawful research route could be absorbed through Puerto Rico’s existing controlled-substances structure. Until then, professional readers should assume low policy momentum, modest ecosystem depth and limited verified research visibility.###